NASDAQ:VNDA
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc.'s revenue grew 8.7% in fiscal 2025 to $216.1M while operating margin fell to −70.0%, its lowest in 10 years. Free cash flow was −$110.4M, −51.1% of revenue, and the diluted share count rose 1.3%.Summary generated from Vanda Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Feb 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$216.1M
Revenue growth+8.7%
Revenue, 5-yr CAGR−2.7%
Gross marginn/a
Operating margin−70.0%
Net margin−102.0%
ROICn/a
Return on equity−50.9%
Debt / equityn/a
Free cash flow−$110.4M
FCF margin−51.1%
Share count change+1.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 269 | 254 | 193 | 199 | 216 |
| Operating income | 42 | 6 | −14 | −41 | −151 |
| Net income | 33 | 6 | 3 | −19 | −220 |
| Free cash flow | 64 | 31 | 12 | −16 | −110 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 4Insider transaction report
Jun 8, 2026 - 4Insider transaction report
Jun 8, 2026 - 8-KResults of a shareholder vote
Jun 5, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 6, 2026 - DEF 14AProxy statement
Apr 23, 2026